104 related articles for article (PubMed ID: 26149376)
1. Isocitrate Dehydrogenase Genes.
Tsamaloukas A
Dtsch Arztebl Int; 2015 May; 112(21-22):372. PubMed ID: 26149376
[No Abstract] [Full Text] [Related]
2. Update on cholangiocarcinoma: potential impact of genomic studies on clinical management.
Walter D; Hartmann S; Waidmann O
Z Gastroenterol; 2017 Jun; 55(6):575-581. PubMed ID: 28376540
[TBL] [Abstract][Full Text] [Related]
3. Liver Mass in a Young Male With Ollier Disease.
Govalan R; Guindi M; Yang JD
Gastroenterology; 2021 Nov; 161(5):e4-e5. PubMed ID: 33812890
[No Abstract] [Full Text] [Related]
4. IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications.
Borger DR; Zhu AX
Expert Rev Anticancer Ther; 2012 May; 12(5):543-6. PubMed ID: 22594888
[No Abstract] [Full Text] [Related]
5. Cancer-associated isocitrate dehydrogenase mutations.
Yen KE; Schenkein DP
Oncologist; 2012; 17(1):5-8. PubMed ID: 22234630
[TBL] [Abstract][Full Text] [Related]
6. Isocitrate Dehydrogenase Mutations in Cholangiocarcinoma: Still a Long Road Ahead.
Nichetti F; Niger M
JCO Precis Oncol; 2022 Apr; 6():e2200065. PubMed ID: 35507887
[No Abstract] [Full Text] [Related]
7. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
[TBL] [Abstract][Full Text] [Related]
8. Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma.
Kipp BR; Voss JS; Kerr SE; Barr Fritcher EG; Graham RP; Zhang L; Highsmith WE; Zhang J; Roberts LR; Gores GJ; Halling KC
Hum Pathol; 2012 Oct; 43(10):1552-8. PubMed ID: 22503487
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma.
Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M
Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804
[TBL] [Abstract][Full Text] [Related]
10. Cholangiocarcinoma: Present Status and Molecular Aspects of Diagnosis.
Liu XF; Tang K; Sui LL; Xu G
Oncol Res; 2014; 22(4):177-183. PubMed ID: 26351206
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma.
Liang Z; Liu X; Zhang Q; Wang C; Zhao Y
Dig Liver Dis; 2016 Oct; 48(10):1227-32. PubMed ID: 27476468
[TBL] [Abstract][Full Text] [Related]
12. miRNA profiling for diagnosis, prognosis and stratification of cancer treatment in cholangiocarcinoma.
Puik JR; Meijer LL; Le Large TY; Prado MM; Frampton AE; Kazemier G; Giovannetti E
Pharmacogenomics; 2017 Sep; 18(14):1343-1358. PubMed ID: 28832247
[TBL] [Abstract][Full Text] [Related]
13. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
Corrigan L; Lowery M
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
[No Abstract] [Full Text] [Related]
14. IDH1 as a frequently mutated gene has potential effect on exosomes releasement by epigenetically regulating P2RX7 in intrahepatic cholangiocarcinoma.
Zhang X; Miao R; Liu T; Xiang X; Gu J; Jia Y; Li Z; Fu Y; He Y; Zhang Y; Zhang J; Qu K; Liu C
Biomed Pharmacother; 2019 May; 113():108774. PubMed ID: 30889491
[TBL] [Abstract][Full Text] [Related]
15. "OMICS" technologies and their role in foregut primary malignancies.
Farid SG; Morris-Stiff G
Curr Probl Surg; 2015 Oct; 52(10):409-41. PubMed ID: 26527526
[No Abstract] [Full Text] [Related]
16. Serum miR-26a as a diagnostic and prognostic biomarker in cholangiocarcinoma.
Wang LJ; Zhang KL; Zhang N; Ma XW; Yan SW; Cao DH; Shi SJ
Oncotarget; 2015 Jul; 6(21):18631-40. PubMed ID: 26087181
[TBL] [Abstract][Full Text] [Related]
17. IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma.
Zhu Y; Kwong LN
Cancer Discov; 2022 Mar; 12(3):604-605. PubMed ID: 35257150
[TBL] [Abstract][Full Text] [Related]
18. Cholangiocarcinoma: State-of-the-art knowledge and challenges.
Banales JM; Cardinale V; Macias RIR; Andersen JB; Braconi C; Carpino G; Alvaro D; Calvisi DF
Liver Int; 2019 May; 39 Suppl 1():5-6. PubMed ID: 31111668
[No Abstract] [Full Text] [Related]
19. [Ivosidenib in the treatment of patients with cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy].
Rabehi T; Quesada S
Bull Cancer; 2023 Dec; 110(12):1230-1231. PubMed ID: 37704495
[No Abstract] [Full Text] [Related]
20. Advances in the diagnosis of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Moreno Luna LE; Gores GJ
Liver Transpl; 2006 Nov; 12(11 Suppl 2):S15-9. PubMed ID: 17051561
[No Abstract] [Full Text] [Related]
[Next] [New Search]
